d3 Medicine LLC, an expert biopharmaceutical strategic advisory company, and Viroclinics Biosciences BV, a virology service organization, announced today that they have signed a non-exclusive Memorandum of Understanding to provide biopharmaceutical customers with an integrated solution to accelerate the preclinical and clinical development of drugs, biologicals, vaccines and diagnostics targeting viral infectious diseases.

The alliance leverages the strengths of the two companies and will offer services that enable biopharmaceutical customers to accelerate virological investigational agents through preclinical and clinical development to market launch. Viroclinics Biosciences will provide a range of preclinical and clinical diagnostic services, including high throughput serology, virology and molecular assays, phenotyping and genotyping in both translational studies and phase I-IV clinical studies, and clinical trial logistics services. d3 Medicine will formulate integrated development, clinical pharmacology and translational medicine strategies to fast-track preclinical development and define customised pharmacometric and quantitative pharmacological approaches to improve decision making and accelerate clinical and regulatory development.

“Biopharmaceutical companies now can turn to d3 Medicine and Viroclinics Biosciences to develop and implement their preclinical, clinical and regulatory strategies when developing therapeutics, vaccines and diagnostics for viral infectious diseases,” said Dr Craig Rayner, CEO and co-Founder of d3 Medicine.

“We are delighted to be able to work more formally with the team at d3 Medicine,” said Dr Bob van Gemen, CEO of Viroclinics Biosciences.“They have great credibility in the market and when combined with the unique virology capabilities and expertise of Viroclinics Biosciences, we believe that through our partnership we offer customers the most comprehensive and exciting range of development services available in the virology field. We can support our biopharmaceutical customers with the best virological knowledge available and provide them with integrated and optimally customised development programs and project solutions.”